Targets › CD96
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Aug 2029.
May be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response. Promotes NK cell-target adhesion by interacting with PVR present on target cells. (UniProt, P40200)
Open in Phaseline: the race on CD96, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Chicago | Volrustomig CD96 antagonist monoclonal antibody | CD96 | Phase 2 | Head and Neck Cancer | Aug 2029 |
Head and Neck Cancer (1)
mixed (1)
University of Chicago (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.